Oncology has long been pharma’s biggest bucket for R&D, with investment historically leading to some of pharma’s most impactful breakthroughs. Learn more in
this Trendline.
Walloping tariffs and stiff pricing policies menace pharma’s horizon. Together, President Donald Trump’s threats put the industry between a rock and a hard place. While very little is certain, drugmakers will likely need to make major changes to their businesses. To meet the moment, according to one Deloitte analyst, pharma leaders could learn a lesson from the not-so-distant past.
“COVID was a significant example of public-private collaborations emerging in ways that moved innovation forward and became the norm,” said Jay Bhatt, managing director of the Deloitte Center for Health Solutions. “In the same way, connecting the dots and multi-disciplinary approaches to address these new challenges could be an opportunity to adopt a hyper-adaptive approach.”
Today, we spoke to Bhatt about how drugmakers can embrace a “quantum” mindset to react to uncertainty stemming from tariffs and pricing restrictions while also continuing to innovate and grow.
Thanks for reading.
Michael Gibney Senior Editor & Writer, PharmaVoice Email
With so many unknowns surrounding regulatory and policy shifts, pharma companies might need to consider fundamental changes to how they operate, a Deloitte analyst said.
As lentiviral vector production becomes more complex and expensive, learn how cell and gene therapy developers can balance cost-efficiency with performance and streamline development in this infographic.
PharmaVoice readers who said that more drugs should be approved using the accelerated approval process, evenly split with those who said there should not be more.
Budget cuts are forcing pharma teams to rethink medical communications strategies for maximum impact. See how industry leaders are doing more with less in this infographic.
